MAP2K7 and ovarian carcinoma: We have shown that a combination of SRC and MEK inhibitors synergistically inhibits the growth of saracatinib resistant ovarian cancer cells, and so we propose that ovarian cancer patients are more likely to respond to SRC inhibition in combination with MEK inhibition.